Jamie L Kuck1, Julie A Bastarache2, Ciara M Shaver1, Joshua P Fessel3, Sergey I Dikalov4, James M May5, Lorraine B Ware6. 1. Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 2. Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. 3. Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA. 4. Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA. 5. Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 6. Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: lorraine.ware@vanderbilt.edu.
Abstract
BACKGROUND: Increased endothelial permeability is central to shock and organ dysfunction in sepsis but therapeutics targeted to known mediators of increased endothelial permeability have been unsuccessful in patient studies. We previously reported that cell-free hemoglobin (CFH) is elevated in the majority of patients with sepsis and is associated with organ dysfunction, poor clinical outcomes and elevated markers of oxidant injury. Others have shown that Vitamin C (ascorbate) may have endothelial protective effects in sepsis. In this study, we tested the hypothesis that high levels of CFH, as seen in the circulation of patients with sepsis, disrupt endothelial barrier integrity. METHODS: Human umbilical vein endothelial cells (HUVEC) were grown to confluence and treated with CFH with or without ascorbate. Monolayer permeability was measured by Electric Cell-substrate Impedance Sensing (ECIS) or transfer of 14C-inulin. Viability was measured by trypan blue exclusion. Intracellular ascorbate was measured by HPLC. RESULTS: CFH increased permeability in a dose- and time-dependent manner with 1 mg/ml of CFH increasing inulin transfer by 50% without affecting cell viability. CFH (1 mg/ml) also caused a dramatic reduction in intracellular ascorbate in the same time frame (1.4 mM without CFH, 0.23 mM 18 h after 1 mg/ml CFH, p < 0.05). Pre-treatment of HUVECs with ascorbate attenuated CFH induced permeability. CONCLUSIONS: CFH increases endothelial permeability in part through depletion of intracellular ascorbate. Supplementation of ascorbate can attenuate increases in permeability mediated by CFH suggesting a possible therapeutic approach in sepsis.
BACKGROUND: Increased endothelial permeability is central to shock and organ dysfunction in sepsis but therapeutics targeted to known mediators of increased endothelial permeability have been unsuccessful in patient studies. We previously reported that cell-free hemoglobin (CFH) is elevated in the majority of patients with sepsis and is associated with organ dysfunction, poor clinical outcomes and elevated markers of oxidant injury. Others have shown that Vitamin C (ascorbate) may have endothelial protective effects in sepsis. In this study, we tested the hypothesis that high levels of CFH, as seen in the circulation of patients with sepsis, disrupt endothelial barrier integrity. METHODS:Human umbilical vein endothelial cells (HUVEC) were grown to confluence and treated with CFH with or without ascorbate. Monolayer permeability was measured by Electric Cell-substrate Impedance Sensing (ECIS) or transfer of 14C-inulin. Viability was measured by trypan blue exclusion. Intracellular ascorbate was measured by HPLC. RESULTS:CFH increased permeability in a dose- and time-dependent manner with 1 mg/ml of CFH increasing inulin transfer by 50% without affecting cell viability. CFH (1 mg/ml) also caused a dramatic reduction in intracellular ascorbate in the same time frame (1.4 mM without CFH, 0.23 mM 18 h after 1 mg/ml CFH, p < 0.05). Pre-treatment of HUVECs with ascorbate attenuated CFH induced permeability. CONCLUSIONS:CFH increases endothelial permeability in part through depletion of intracellular ascorbate. Supplementation of ascorbate can attenuate increases in permeability mediated by CFH suggesting a possible therapeutic approach in sepsis.
Authors: Niels B J Vollaard; Brandon J Reeder; Jerry P Shearman; Patrick Menu; Michael T Wilson; Chris E Cooper Journal: Free Radic Biol Med Date: 2005-08-10 Impact factor: 7.376
Authors: David R Janz; Julie A Bastarache; Josh F Peterson; Gillian Sills; Nancy Wickersham; Addison K May; L Jackson Roberts; Lorraine B Ware Journal: Crit Care Med Date: 2013-03 Impact factor: 7.598
Authors: Ciara M Shaver; Melinda G Paul; Nathan D Putz; Stuart R Landstreet; Jamie L Kuck; Lauren Scarfe; Nataliya Skrypnyk; Haichun Yang; Fiona E Harrison; Mark P de Caestecker; Julie A Bastarache; Lorraine B Ware Journal: Am J Physiol Renal Physiol Date: 2019-07-31
Authors: William S Dodd; Devan Patel; Brandon Lucke-Wold; Koji Hosaka; Nohra Chalouhi; Brian L Hoh Journal: Biochem Biophys Res Commun Date: 2021-10-16 Impact factor: 3.575
Authors: David C Consoli; Jordan J Jesse; Kelly R Klimo; Adriana A Tienda; Nathan D Putz; Julie A Bastarache; Fiona E Harrison Journal: Nutrients Date: 2020-03-26 Impact factor: 5.717
Authors: Judit Erdei; Andrea Tóth; Andrea Nagy; Benard Bogonko Nyakundi; Zsolt Fejes; Béla Nagy; László Novák; László Bognár; Enikö Balogh; György Paragh; János Kappelmayer; Attila Bácsi; Viktória Jeney Journal: Front Immunol Date: 2020-03-06 Impact factor: 7.561